Recent News

Upcoming Seminars and Events

View upcoming seminars and events.

Learn more
567 News Items found
PET/CT scan of mouse prostate (displayed in green and orange).
In the Lab
More Precise Imaging of Prostate Cancer Could Give Insight into Drug Effectiveness

An antibody that targets a protein specific to prostate cells can be used to image prostate cancer more clearly and indicate how well drugs are working.
T cells on the loose.
Feature
T Is for T Cell: The Science Behind Immunotherapy

By deciphering the biology of T cells, MSK scientists gave immunotherapy a boost.
Image of fireball-type explosion on black background.
In the Lab
Researchers Gain Insight into How a Drug Fires Up an Immune Response to Cancer

Scientists have learned that a drug activates a form of highly inflammatory programmed cell death called pyroptosis — a discovery that sheds light on immune function.
Illustration of immune cell opening as if on hinge and boxing glove coming out.
Q&A
New Approach Could Boost Immunotherapy for Breast Cancer

A protein on certain immune cells is a promising target for making immunotherapy more effective against breast cancer.
a circuit board
Feature
After Years of Neglect, Cancer Biologists Return to a Forgotten Field: Metabolism

Scientists are dusting off their biochemistry textbooks in the hunt for clues to cancer.
Bees in a hive
In the Lab
Communal Behavior within Cells Makes Cancers Easier to Target

Findings about proteins called molecular chaperones are shedding new light on possible approaches to cancer treatment.
A chess match
In the Lab
Resistance Is Futile: Targeted Treatment Makes Stubborn Cancers Responsive to Immunotherapy

New research on an experimental drug provides hope for better responses to immunotherapy.
Christine Mayr, MD, PhD
Molecular Biologist Christine Mayr of Sloan Kettering Institute Honored with Prestigious NIH Director’s Pioneer Award

Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and supports individual scientists of exceptional creativity who propose pioneering and highly innovative approaches with the potential to produce an unusually high impact on biomedical or behavioral research.
Memorial Sloan Kettering Researchers Engineer “Micro-Pharmacies” in CAR T Cells to Treat B Cell Lymphomas

There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells. Historically, CAR T cell immunotherapy has aimed to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them. New work led by Hans-Guido Wendel, MD, of Memorial Sloan Kettering Cancer Center (MSK), and collaborator Karin Tarte of the University of Rennes, France, illustrates an untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery.
Illustration of CAR T cells with conveyor belts leading out of them carrying HVEM protein in tablet form.
In the Lab
New Immunotherapy Approach Turns Cells into “Micro-Pharmacies”

A new immunotherapy approach involves engineering CAR T cells to produce proteins that treat lymphoma.